The Committee discusses and makes recommendations on BrainStorm Cell Therapeutics Biologics License Application (BLA) 125782 for Debamestrocel (autologous bone marrow-derived mesenchymal stromal cells induced to secrete neurotrophic factors). The applicant has requested an indication for treatment of Amyotrophic Lateral Sclerosis (ALS). The Virtual Meeting will be held on September 27 at 10 am. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BCLI:
- Largest borrow rate increases among liquid names
- BrainStorm announces Nasdaq halts trading of company’s common stock
- FDA Cellular, Tissue, and Gene Therapies Advisory Committee Virtual Meeting
- BrainStorm falls 40% as FDA highlights concerns with NurOwn to AdCom
- BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
